Ultrasound peripheral developer EchoCath received Food and DrugAdministration 510(k) approval in September for its ColorMarkdevice for improving needle visualization during ultrasound-guidedbiopsy. The device consists of a vibrating clip attached to a
Ultrasound peripheral developer EchoCath received Food and DrugAdministration 510(k) approval in September for its ColorMarkdevice for improving needle visualization during ultrasound-guidedbiopsy.
The device consists of a vibrating clip attached to a biopsyneedle. The vibration creates a phase shift that shows up as amultihued stripe on color-flow Doppler scanners. EchoCath unveiledthe technology at the American Institute of Ultrasound in Medicinemeeting in March (SCAN 5/19/93).
ColorMark could aid the transition of biopsy procedures fromCT to ultrasound, as well as increase the accuracy of fine-needleaspiration biopsy, the manufacturer said. EchoCath is developinga ColorMark system for the Bard biopsy gun.
The firm is gearing up production of ColorMark devices andintends to begin shipping product in the first quarter of nextyear.
BRIEFLY NOTED:
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.